ESMO-MCBS and health technology assessment (HTA): Does value for physicians correspond to value for payers?

被引：0
|
作者：
Ambavane, A. [1 ]
Benedict, A. [2 ]
Rivolo, S. [3 ]
Rakonczai, P. [2 ]
Kapetanakis, V. [4 ]
机构：
[1] Evidera Inc, Evidence Synth Modeling & Commun, Dubai, U Arab Emirates
[2] Evidera Inc, Evidence Synth Modeling & Commun, Budapest, Hungary
[3] Evidera Inc, Evidence Synth Modeling & Commun, Angera, Italy
[4] Evidera Inc, Evidence Synth Modeling & Commun, London, England
来源：
ANNALS OF ONCOLOGY | 2019年 / 30卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1626O
引用
收藏
页码：671 / 671
页数：1
相关论文
共 50 条
  • [1] Assessing the value of new cancer drugs for regulatory and HTA decisions e the role of ESMO-MCBS
    Gyawali, B.
    ANNALS OF ONCOLOGY, 2024, 35 : S1277 - S1277
  • [2] Is there a link between value as defined by ESMO-MCBS and uptake of new drugs?
    Lindgren, Peter
    Jonsson, Bengt
    Hofmarcher, Thomas
    Wilking, Nils Erik
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [3] The value measurement of emerging therapeutics in renal cell carcinoma: ASCO value framework and ESMO-MCBS
    Ha, Hyerim
    Kang, Jin Hyoung
    Kim, Do Yeun
    Bae, Seung Jin
    Lee, Hee Yeon
    BMC HEALTH SERVICES RESEARCH, 2022, 22 (01)
  • [4] The value measurement of emerging therapeutics in renal cell carcinoma: ASCO value framework and ESMO-MCBS
    Hyerim Ha
    Jin Hyoung Kang
    Do Yeun Kim
    Seung Jin Bae
    Hee Yeon Lee
    BMC Health Services Research, 22
  • [5] VALUE FOR PAYERS VS. PHYSICIANS: IS THERE CONVERGENCE BETWEEN VALUE ASSESSMENT BY ESMO, ASCO AND UK NICE DECISION?
    Rivolo, S.
    Ambavane, A.
    Rakonczai, P.
    Kapetanakis, V
    Benedict, A.
    VALUE IN HEALTH, 2019, 22 : S98 - S99
  • [6] Choosing PD-1 Inhibitors in Oncology Setting, Left or Right?-Lessons From Value Assessment With ASCO-VF and ESMO-MCBS
    Jiang, Qian
    Feng, Mei
    Li, Youping
    Lang, Jinyi
    Wei, Hua
    Yu, Ting
    FRONTIERS IN PHARMACOLOGY, 2020, 11
  • [7] The Experience of Patients in Chronic Care Management: Applications in Health Technology Assessment (HTA) and Value for Public Health
    Pennestri, Federico
    Banfi, Giuseppe
    INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH, 2022, 19 (16)
  • [8] THE VALUE OF REAL-WORLD EVIDENCE (RWE) IN MELANOMA IN HEALTH TECHNOLOGY ASSESSMENT (HTA) APPRAISALS
    Shah, R.
    Gautam, R.
    Rai, M. K.
    Prasanna, R.
    VALUE IN HEALTH, 2022, 25 (12) : S317 - S317
  • [9] THE ADDED VALUE OF INTEGRATE-HTA GUIDANCE IN THE WORK PROCESSES OF HEALTH TECHNOLOGY ASSESSMENT AGENCIES
    van der Wilt, Gert Jan
    Kievit, Wietske
    Oortwijn, Wija
    INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE, 2017, 33 (05) : 597 - 598
  • [10] US drug marketing: how does promotion correspond with health value?
    Greenway, Tyler
    Ross, Joseph S.
    BMJ-BRITISH MEDICAL JOURNAL, 2017, 357
12345